Global Gut Microbiome Market Size Likely to Reach at a CAGR of 17.1% By 2033

As per the current market research conducted by the CMI Team, the global Gut Microbiome Market size is expected to record a CAGR of 17.1% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 717.2 Million. By 2033, the valuation is anticipated to reach USD 2,969.4 Million.

Gut Microbiome Market: Growth Factors and Dynamics

• Increasing Awareness of Gut Health: Growing awareness among consumers about the importance of gut health and its impact on overall well-being is driving the demand for gut microbiome products. Consumers are increasingly seeking solutions to maintain a healthy gut microbiome, leading to the expansion of the market.

• Advancements in Microbiome Research: Ongoing advancements in microbiome research are uncovering the intricate relationship between gut microbiota and various health conditions. As scientific understanding deepens, there’s a surge in the development of gut microbiome-based therapies, diagnostics, and interventions, fueling market growth.

• Rising Prevalence of Digestive Disorders: The increasing prevalence of digestive disorders such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and gastrointestinal infections is driving the demand for gut microbiome products. Consumers are turning to probiotics, prebiotics, and other gut health supplements to manage symptoms and improve digestive health.

• Expansion of Functional Food and Beverage Market: The growing market for functional foods and beverages, which are fortified with probiotics, prebiotics, and other gut-friendly ingredients, is contributing to the growth of the gut microbiome market. Manufacturers are innovating with product formulations to meet consumer demand for gut health-enhancing products.

• Healthcare Shift Towards Personalized Medicine: The healthcare industry’s shift towards personalized medicine and precision nutrition is driving the adoption of gut microbiome-based diagnostics and therapeutics. Tailoring treatments and interventions based on an individual’s gut microbiome profile is becoming increasingly common, driving demand for microbiome testing kits and personalized nutrition solutions.

• Investments and Collaborations in Microbiome Science: Increased investments from pharmaceutical companies, biotechnology firms, and research institutions in microbiome science are accelerating product development and commercialization in the gut microbiome market. Collaborations between academia and industry players are driving innovation and expanding the range of gut microbiome-based products and services available to consumers.

Gut Microbiome Market: Partnership and Acquisitions

• In 2022, Seres Therapeutics Inc. successfully submitted its BLA application to the FDA for SER-109, a novel treatment aiming to prevent recurrent C. difficile infection (rCDI). Representing a new treatment approach, SER-109 holds the potential to enhance the existing standard of care for rCDI.

• In 2023, Vedanta Biosciences secured USD 106.5 million in financing to advance its pipeline of defined bacterial consortia therapies. The funding will primarily support a pivotal Phase III trial of VE303, aimed at preventing recurrent C. difficile Infection (CDI), demonstrating the company’s commitment to microbiome-based treatments.

Report Scope

Gut Microbiome Market: COVID-19 Analysis

The COVID-19 pandemic has had a significant impact on the Gut Microbiome Market, with the industry experiencing both positive and negative effects. Here are some of the key impacts:

• Disrupted Supply Chains: The COVID-19 pandemic disrupted global supply chains, affecting the availability and distribution of gut microbiome products such as probiotics and prebiotics. Manufacturing delays and logistics challenges hindered the supply of these products to consumers, impacting market growth.

• Shift in Consumer Priorities: During the pandemic, there was a shift in consumer priorities towards essentials, leading to a temporary decline in demand for non-essential health supplements, including gut microbiome products. Economic uncertainties and changes in spending patterns affected consumer purchasing behavior, impacting market dynamics.

• Focus on Immune Health: With heightened awareness of health and wellness post-pandemic, there’s an increased focus on immune health, driving demand for gut microbiome products known to support immune function. Manufacturers can capitalize on this trend by promoting the immune-boosting properties of probiotics and other gut health supplements.

• Expansion of E-commerce: The pandemic accelerated the shift towards online shopping, including the purchase of health supplements. Manufacturers and retailers can leverage e-commerce channels to reach consumers directly, offering convenience and accessibility for purchasing gut microbiome products, thus facilitating market recovery.

• Innovations in Product Formulations: Companies can invest in research and development to innovate new product formulations that address specific health concerns heightened by the pandemic, such as stress management, mental health, and gastrointestinal issues. Novel ingredients and delivery systems can enhance the efficacy and appeal of gut microbiome products.

• Healthcare Professional Recommendations: Collaborations with healthcare professionals and nutritionists can help promote gut microbiome products as part of a holistic approach to health and wellness. Endorsements from trusted experts can instill confidence in consumers and drive demand for gut health supplements, aiding market recovery.

• Educational Campaigns: Increasing consumer education about the importance of gut health and the role of gut microbiome products in supporting overall well-being can stimulate market demand. Educational campaigns through social media, online platforms, and traditional media channels can raise awareness and encourage consumers to prioritize gut health post-pandemic.

In conclusion, the COVID-19 pandemic has had a mixed impact on the Gut Microbiome Market, with some challenges and opportunities arising from the pandemic.

List of the prominent players in the Gut Microbiome Market:

• DuPont de Nemours Inc.
• Yakult Honsha Co. Ltd.
• Nestlé Health Science
• BioGaia AB
• Hansen Holding A/S
• Procter & Gamble Company
• Bayer AG
• Pfizer Inc.
• Johnson & Johnson
• Novartis International AG
• Abbott Laboratories
• Kerry Group plc
• DSM Nutritional Products AG
• ADM Protexin Ltd.
• Danone S.A.
• Others

The Gut Microbiome Market is segmented as follows:

By Product Type

• Probiotics
• Prebiotics
• Food supplements
• Drugs and medications
• Diagnostic kits and tools
• Others

By Application

• Digestive health
• Immune system support
• Weight management
• Mental health and cognition
• Skin health
• Others

By End User

• Healthcare providers
• Food and beverage industry
• Dietary supplement manufacturers
• Research institutions
• Direct-to-consumer
• Others

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America